Immune Design, Sanofi Pasteur to develop herpes simplex virus therapy
As part of the development, Sanofi Pasteur will contribute HSV-529, a clinical-stage replication-defective HSV vaccine product candidate, while Immune Design will provide its preclinical trivalent vaccine product candidate
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.